PrEP RCT healthcare workers in Spain, showing no significant
difference in cases with melatonin prophylaxis. Most cases were asymptomatic
or paucisymtomatic, there were two symptomatic cases, no moderate/severe
cases, and no hospitalization.
The registered primary outcome is symptomatic cases. Authors
report on all cases due to the small number of symptomatic cases. They did not
include the original primary outcome results in the paper, but have provided
the results via email to a contributor.
The dosage in this trial is very low, 2mg daily. Meta
regression suggests higher doses are much more effective.
García-García et al., 2/21/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Spain, Europe, peer-reviewed, 25 authors.